Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors
Oudah, Khulood H; Najm, Mazin A A; Samir, Nermin; Serya, Rabah; Khaled A M Abouzid;
Abstract
Cyclin Dependent Kinases CDKs unpredictable activity has been accounted for a wide assortment of human malignancies, so it might be conceivable to design pharmacologically relevant ligands that go about as specific and potent inhibitors of CDK2 action. In this respect, a series of novel pyrazolo[1,5-a][1,3,5]triazine derivatives were designed, synthesized and evaluated for CDK2 enzyme inhibitory and anticancer activity. Compounds 9f and 10c showed best CDK2 inhibition among the newly synthesized compounds, with percent inhibition at 82.38%, and 81.96% against CDK2 and IC50 of 1.85 and 2.09 µM, respectively. Additionally, the newly synthesized compounds were tested for their antiproliferative activity against 60 NCI cell lines. Molecular docking revealed the binding mode of these new compounds into the roscovitine binding site of CDK2 enzyme (PDB code: 3ddq). Conclusively, pyrazolotriazine derivatives represent a talented starting point for further study as anticancer drug.
Other data
Title | Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors | Authors | Oudah, Khulood H; Najm, Mazin A A; Samir, Nermin; Serya, Rabah ; Khaled A M Abouzid | Keywords | Anticancer; CDK2 inhibitors; Docking; Purine bioisostere; Pyrazolo[1,5-a][1,3,5]triazine | Issue Date | 2019 | Publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | Journal | Bioorganic chemistry | Volume | 92 | Start page | 103239 | ISSN | 0045-2068 | DOI | 10.1016/j.bioorg.2019.103239 | PubMed ID | 31513938 | Scopus ID | 2-s2.0-85071913709 | Web of science ID | WOS:000489699400026 |
Attached Files
File | Description | Size | Format | Existing users please Login |
---|---|---|---|---|
7.pdf | 3.32 MB | Adobe PDF | Request a copy |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.